Emerging oral drugs for psoriasis

Expert Opinion on Emerging Drugs

Volumn 20, Issue 2, 2015, Pages 209-220

  Mahmood, Tahmina ^a   Zaghi, Daniel ^b   Menter, Alan ^b  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Oral; Psoriasis; Systemic medication; Therapeutics

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADALIMUMAB; ALITRETINOIN; ANTIPSORIASIS AGENT; APREMILAST; BARICITINIB; CYCLOSPORIN; ETANERCEPT; ETRETIN; FP 187; FUMARIC ACID DERIVATIVE; GSK 2586184; INFLIXIMAB; INTERLEUKIN 17; JANUS KINASE INHIBITOR; KD 025; METHOTREXATE; ORILOTIMOD; PEFICITINIB; PHOSPHOLIPID DERIVATIVE; PONESIMOD; RHO KINASE INHIBITOR; SECUKINUMAB; TOFACITINIB; TOPICAL AGENT; UNCLASSIFIED DRUG; USTEKINUMAB; VB 201; DERMATOLOGICAL AGENT; THALIDOMIDE;

ARTHRALGIA; BIOLOGICAL THERAPY; CLINICAL FEATURE; COMORBIDITY; DACTYLITIS; DISEASE SEVERITY; ENTHESITIS; ENVIRONMENTAL FACTOR; ERYTHRODERMIC PSORIASIS; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; GUTTATE PSORIASIS; HEALTH CARE NEED; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMPETIGO HERPETIFORMIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; PREVALENCE; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RIGIDITY; SKIN DEFECT; SYSTEMIC THERAPY; TOPICAL TREATMENT; ANALOGS AND DERIVATIVES; ANIMAL; DRUG APPROVAL; DRUG DESIGN; ORAL DRUG ADMINISTRATION; PATHOLOGY; SEVERITY OF ILLNESS INDEX; UNITED STATES;

ADMINISTRATION, ORAL; ANIMALS; DERMATOLOGIC AGENTS; DRUG APPROVAL; DRUG DESIGN; HUMANS; PSORIASIS; SEVERITY OF ILLNESS INDEX; THALIDOMIDE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84930021077     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2015.1010509     Document Type: Review

References (59)

1. Kivelevitch DN, Hebeler KR, Patel M, et al. Emerging topical treatments for psoriasis. Expert Opin Emerg Drugs 2013;18(4):523-32
2. Patel M, Day A, Warren RB, et al. Emerging therapies for the treatment of psoriasis. Dermatol Ther (HeiDelb) 2012;2(1):16
3. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361(5):496-509
4. Gottlieb A, Korman NJ, Gordon KB, et al. GuiDelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guiDelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64
5. Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 2014;74(4):423-41
6. LLC MB. Medical adVances may help improve psoriasis outcomes. Life Science Digest 2012;1-14. Available publication of some of the agents Described in the article and proviDes more data about the tirals Described
7. Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med 2014;4:8
8. Roth MM. Pregnancy Dermatoses: diagnosis, management, and controversies. Am J Clin Dermatol 2011;12(1):25-41
9. Boyd AS, Menter A. ErythroDermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol 1989;21(5 Pt 1):985-91
10. Bowcock AM, Barker JN. Genetics of psoriasis: the potential impact on new therapies. J Am Acad Dermatol 2003;49(2 Suppl):S51-6
11. Nickoloff BJ, Turka LA, Mitra RS, et al. Direct and indirect control of T-cell activation by keratinocytes. J Invest Dermatol 1995;105(1 Suppl):25S-9S
12. Becher B, Pantelyushin S. Hiding unDer the skin: interleukin-17-producing gammaDelta T cells go unDer the skin?Nat med 2012;18(12):1748-50
13. Krueger JG. Hiding unDer the skin: A welcome surprise in psoriasis. Nat med 2012;18(12):1750-1
14. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356(6):580-92
15. Zhu B, Edson-Heredia E, Cameron GS, et al. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase study of patients with moDerate-to-severe plaque psoriasis. Br J Dermatol 2013;169(6):1337-41
16. Colombo MD, Cassano N, Bellia G, et al. Cyclosporine regimens in plaque psoriasis: An overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal 2013;2013:805705
17. Ng LC, Lee YY, Lee CK, et al. A retrospective review of methotrexateinduced hepatotoxicity among patients with psoriasis in a tertiary Dermatology center in Malaysia. Int J Dermatol 2013;52(1):102-5
18. Hsu L, Armstrong AW. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res 2014;2014:283617
19. Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: An algorithmbased approach for primary care physicians. Am Fam Physician 2000;61(3):725-33
20. Taheri A, Cantrell J, Feldman SR. Tachyphylaxis to topical glucocorticoids; what is the eviDence?Dermatol Online J 2013;19(7):18954
21. Ryan C, Korman NJ, Gelfand JM, et al. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol 2014;70(1):146-67
22. Menter A, Korman NJ, Elmets CA, et al. GuiDelines of care for the management of psoriasis and psoriatic arthritis: section 4. GuiDelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85
23. Salim A, Tan E, Ilchyshyn A, et al. Folic acid supplementation during treatment of psoriasis with methotrexate: A randomized, double-blind, placebocontrolled trial. Br J Dermatol 2006;154(6):1169-74
24. Brownell I, Strober BE. Folate with methotrexate: big benefit, questionable cost. Br J Dermatol 2007;157(1):213
25. Sarkar R, Chugh S, Garg VK. Acitretin in Dermatology. Indian J Dermatol Venereol Leprol 2013;79(6):759-71
26. Kuijpers AL, Van Dooren-Greebe JV, Van De Kerkhof PC. Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythroDermic psoriasis. Dermatology 1997;194(1):88-90
27. Saurat JH. SiDe effects of systemic retinoids and their clinical management. J Am Acad Dermatol 1992;27(6 Pt 2):S23-8
28. McNamara PJ, Jewell RC, Jensen BK, et al. Food increases the bioavailability of acitretin. J Clin Pharmacol 1988;28(11):1051-5
29. Belge K, Bruck J, Ghoreschi K. AdVances in treating psoriasis. F1000Prime Rep 2014;6:4
30. Aslam A, Griffiths CE. Drug therapies in Dermatology. Clin med 2014;14(1):47-53
31. Gelfand JM, Shin DB, Neimann AL, et al the risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126(10):2194-201
32. Lebwohl M. New Developments in the treatment of psoriasis. Arch Dermatol 2002;138(5):686-8
33. Irla N, Navarini AA, Yawalkar N. Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis. Br J Dermatol 2012;167(5):1170-4
34. David M, Akerman L, Ziv M, et al. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol 2012;26(3):361-7
35. Feige E, MenDel I, George J, et al. Modified phospholipids as antiinflammatory compounds. Curr Opin Lipidol 2010;21(6):525-9
36. Ismail N, Collins P, Rogers S, et al. Drug survival of fumaric acid esters for psoriasis: A retrospective study. Br J Dermatol 2014;171(2):397-402
37. Ryan C, Menter A. Ponesimod-A future oral therapy for psoriasis?Lancet 2014;384(9959):2006-8
38. Kadmon. Jefferies healthcare conference, New York City. In: 2014
39. Chang BY, Zhao F, He X, et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol 2009;183(3):2183-92
40. Ortiz-Ibanez K, Alsina MM, Munoz-Santos C. Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas Dermosifiliogr 2013;104(4):304-10
41. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012;167(3):668-77
42. A Phase 3, multi site, randomized, double blind, placebo controlled study of the efficacy and safety comparing CP-690 ,550 and etanercept in subjects with moDerate to severe chronic plaque psoriasis. 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01241591 [Last accessed 2 November 2014]
43. A study to evaluate the effects and safety of treatment, treatment withdrawal, followed by re-treatment with CP-690 ,550 in subjects with moDerate to severe chronic plaque psoriasis. 2014. Available from: http://clinicaltrials.gov/ct2/show/results/NCT01186744 [Last accessed 2 November 2014]
44. Meier FM, McInnes IB. Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety. Best Pract Res Clin Rheumatol 2014;28(4):605-24
45. Phasea randomized, double-blind, placebo-controlled, sequential doseescalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase (JAK) inhibitor, in patients with moDerate-to-severe psoriasis. In: 3rd World Psoriasis &Psoriatic Arthritis Conference 2012: Psoriasis-A global health challenge; 27 July 1 2012; Stockholm, SweDen
46. Study to evaluate safety and effectiveness of oral apremilast (CC-10004) in patients with moDerate to severe plaque psoriasis (ESTEEM 1). 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01194219 [Last accessed 2 November 2014]
47. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10(22):1503-19
48. Papp K GC, Leonardi C, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moDerate to severe psoriasis: Results from the randomized treatment withdrawal phase of a phase 3, randomized, controlled trial (ESTEEM 1). J Am Acad Dermatology 2014;70:Suppl 1:AB164
49. Papp KA, Kaufmann R, Thaci D, et al. Efficacy and safety of apremilast in subjects with moDerate to severe plaque psoriasis: results from a phase, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dosecomparison study. J Eur Acad Dermatol Venereol 2013;27:e376-83
50. Tan J, Maari C, Nigen S, et al. Open-label exploratory study of acitretin for the treatment of severe chronic hand Dermatitis. J Dermatolog Treat 2014;1-3
51. Trial of CF101 to treat patients with psoriasis. 2014. Available from: http://clinicaltrials.gov/show/NCT01265667 [Last accessed 2 November 2014]
52. Mease PK GD, ADebajo AO, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three phase 3, randomized, controlled trials. In: American College of Rheumatology; 26-30 October 2013; San Diego, CA. 2013
53. Varada S, Tintle SJ, Gottlieb AB. Apremilast for the treatment of psoriatic arthritis. Expert Rev Clin Pharmacol 2014;7(3):239-50
54. A proof of concept study comparing three doses of an oral solution of LEO 22811 with a placebo oral solution for the treatment of psoriasis vulgaris. 2011. Available from: http://clinicaltrials.gov/show/NCT01116895 [Last accessed 2 November 2014]
55. Study to assess VB-201 in patients with psoriasis. 2011. Available from: http://clinicaltrials.gov/show/NCT01001468 [Last accessed 2 November 2014]
56. Olsson T, Boster A, FernanDez O, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: A randomised phase trial. J Neurol Neurosurg Psychiatry 2014;85(11):1198-208
57. Study to evaluate Apo805K1 in subjects with moDerate to severe chronic plaque psoriasis. 2013. Available from: http://clinicaltrials.gov/show/NCT01483924 [Last accessed 2 November 2014]
58. A safety and tolerability study of KD025 treatment in subjects with moDerately severe psoriasis vulgaris. 2014. Available from: http://clinicaltrials.gov/show/NCT02106195 [Last accessed 2 November 2014]
59. Vaclavkova A, Chimenti S, Arenberger P, et al. Oral ponesimod in patients with chronic plaque psoriasis: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014;384(9959):2036-45